|
CU22545A1
(es)
*
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
KR20080059467A
(ko)
*
|
1996-12-03 |
2008-06-27 |
아브게닉스, 인크. |
복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
|
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US6235883B1
(en)
*
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
|
DE69942607D1
(de)
|
1998-04-14 |
2010-09-02 |
Chugai Pharmaceutical Co Ltd |
Neues cytokinartiges protein
|
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
|
AR022952A1
(es)
*
|
1999-03-19 |
2002-09-04 |
Smithkline Beecham Corp |
ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
CZ20014083A3
(cs)
*
|
1999-05-14 |
2002-08-14 |
Imclone Systems Incorporated |
Léčivo pro indikaci růstu refrakterních nádorů
|
|
CN100340575C
(zh)
|
1999-06-25 |
2007-10-03 |
杰南技术公司 |
人源化抗ErbB2抗体及其在制备药物中的应用
|
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
|
PT1270595E
(pt)
*
|
2000-03-03 |
2008-09-16 |
Kyowa Hakko Kogyo Kk |
Anticorpo recombinante de genes e os seus fragmentos
|
|
AU2001258567A1
(en)
*
|
2000-05-19 |
2001-11-26 |
Scancell Limited |
Humanised antibodies to the epidermal growth factor receptor
|
|
AU2001295002B2
(en)
*
|
2000-08-09 |
2007-05-31 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
ES2318649T3
(es)
|
2000-10-20 |
2009-05-01 |
EISAI R&D MANAGEMENT CO., LTD. |
Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
|
|
CU22979A1
(es)
*
|
2000-12-08 |
2004-09-09 |
Centro Inmunologia Molecular |
Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
|
|
US7319139B2
(en)
|
2001-01-29 |
2008-01-15 |
Biogen Idec, Inc. |
TAG-72 specific CH2 domain deleted antibodies
|
|
IL157142A0
(en)
*
|
2001-01-29 |
2004-02-08 |
Idec Pharma Corp |
Modified antibodies and methods of use
|
|
ES2398099T3
(es)
*
|
2001-02-19 |
2013-03-13 |
Merck Patent Gmbh |
Anticuerpos anti-EGFR modificados con inmunogenicidad reducida
|
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
|
EP2335728A1
(en)
|
2001-05-11 |
2011-06-22 |
Ludwig Institute for Cancer Research Ltd. |
Specific binding proteins and uses thereof
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
|
ATE477280T1
(de)
*
|
2001-06-28 |
2010-08-15 |
Domantis Ltd |
Doppelspezifischer ligand und dessen verwendung
|
|
US7951061B2
(en)
*
|
2001-07-25 |
2011-05-31 |
Allan Foreman |
Devices for targeted delivery of thermotherapy, and methods related thereto
|
|
US7074175B2
(en)
|
2001-07-25 |
2006-07-11 |
Erik Schroeder Handy |
Thermotherapy via targeted delivery of nanoscale magnetic particles
|
|
US6997863B2
(en)
*
|
2001-07-25 |
2006-02-14 |
Triton Biosystems, Inc. |
Thermotherapy via targeted delivery of nanoscale magnetic particles
|
|
US7731648B2
(en)
*
|
2001-07-25 |
2010-06-08 |
Aduro Biotech |
Magnetic nanoscale particle compositions, and therapeutic methods related thereto
|
|
US20080193445A1
(en)
*
|
2002-01-18 |
2008-08-14 |
Liliane Goetsch |
Novel anti-IGF-IR antibodies and uses thereof
|
|
US7241444B2
(en)
*
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
US20080063639A1
(en)
*
|
2002-01-18 |
2008-03-13 |
Pierre Fabre Medicament |
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
|
|
AU2003217386B2
(en)
*
|
2002-02-13 |
2008-06-26 |
Ludwig Institute For Cancer Research |
Humanized GM-CSF antibodies
|
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7332585B2
(en)
*
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
WO2003084569A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Medicament contenant une composition anticorps
|
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
PT1517921E
(pt)
*
|
2002-06-28 |
2006-09-29 |
Domantis Ltd |
Ligandos duplamente especificos com semi-vida no soro aumentada
|
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
|
JP5069843B2
(ja)
|
2002-07-15 |
2012-11-07 |
ジェネンテック， インコーポレイテッド |
抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
|
|
BRPI0314814C1
(pt)
|
2002-09-27 |
2021-07-27 |
Xencor Inc |
anticorpo compreendendo uma variante de fc
|
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
|
CU23097A1
(es)
|
2002-10-23 |
2005-11-18 |
Centro Inmunologia Molecular |
Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
|
|
PT2316852E
(pt)
*
|
2002-11-08 |
2014-06-23 |
Ablynx Nv |
Anticorpos de domínio único estáveis
|
|
US20060034845A1
(en)
*
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
|
US20100003253A1
(en)
*
|
2002-11-08 |
2010-01-07 |
Ablynx N.V. |
Single domain antibodies directed against epidermal growth factor receptor and uses therefor
|
|
BRPI0316092B8
(pt)
*
|
2002-11-08 |
2021-05-25 |
Ablynx Nv |
anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
|
|
NZ563471A
(en)
*
|
2002-11-08 |
2009-04-30 |
Ablynx Nv |
Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
|
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
US20040147428A1
(en)
*
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
|
JP2006523090A
(ja)
*
|
2002-12-27 |
2006-10-12 |
ドマンティス リミテッド |
リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
|
|
US20040193752A1
(en)
*
|
2003-01-02 |
2004-09-30 |
Harpreet Singh |
System and method for providing fee-based data services
|
|
US20040156846A1
(en)
*
|
2003-02-06 |
2004-08-12 |
Triton Biosystems, Inc. |
Therapy via targeted delivery of nanoscale particles using L6 antibodies
|
|
ATE468886T1
(de)
*
|
2003-02-10 |
2010-06-15 |
Applied Molecular Evolution |
Abeta-bindende moleküle
|
|
US8663650B2
(en)
|
2003-02-21 |
2014-03-04 |
Ac Immune Sa |
Methods and compositions comprising supramolecular constructs
|
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
ATE508747T1
(de)
|
2003-03-10 |
2011-05-15 |
Eisai R&D Man Co Ltd |
C-kit kinase-hemmer
|
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
|
CN101966338A
(zh)
|
2003-06-09 |
2011-02-09 |
塞缪尔·瓦克萨尔 |
用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
|
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
ZA200603619B
(en)
|
2003-11-06 |
2008-10-29 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
|
DK1687338T3
(da)
*
|
2003-11-07 |
2011-02-07 |
Ablynx Nv |
Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf
|
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
|
EP1759010A4
(en)
*
|
2004-01-07 |
2008-12-24 |
Bristol Myers Squibb Co |
BIOMARKERS AND METHOD FOR DETERMINING SENSITIVITY AGAINST MODULATORS OF EGF (EPIDERMAL GROWTH FACTOR) RECEPTORS
|
|
TW200533339A
(en)
*
|
2004-03-16 |
2005-10-16 |
Bristol Myers Squibb Co |
Therapeutic synergy of anti-cancer compounds
|
|
WO2005090407A1
(en)
*
|
2004-03-19 |
2005-09-29 |
Imclone Systems Incorporated |
Human anti-epidermal growth factor receptor antibody
|
|
JP4969440B2
(ja)
|
2004-04-08 |
2012-07-04 |
デビッド， ビー． エイガス， |
疼痛治療のためのＥｒｂＢアンタゴニスト
|
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
|
BRPI0510674A
(pt)
|
2004-07-15 |
2007-12-26 |
Xencor Inc |
variantes fc otimizadas
|
|
FR2873699B1
(fr)
*
|
2004-07-29 |
2009-08-21 |
Pierre Fabre Medicament Sa |
Nouveaux anticorps anti igf ir rt leurs utilisations
|
|
EP1797881B1
(en)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Medicinal composition with improved stability and reduced gelation properties
|
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
DK2325207T3
(en)
|
2004-11-12 |
2017-06-06 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
CN102580084B
(zh)
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
|
WO2006082515A2
(en)
|
2005-02-07 |
2006-08-10 |
Glycart Biotechnology Ag |
Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
|
|
CN103251946A
(zh)
|
2005-02-23 |
2013-08-21 |
健泰科生物技术公司 |
使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
|
|
CN101163468A
(zh)
*
|
2005-02-28 |
2008-04-16 |
卫材R&D管理有限公司 |
磺酰胺化合物的新联合用途
|
|
US20060204505A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
|
US7635570B2
(en)
|
2005-04-01 |
2009-12-22 |
Salvatore Siena |
Epidermal growth factor receptor gene copy number
|
|
CN101228189A
(zh)
*
|
2005-05-09 |
2008-07-23 |
格黎卡特生物技术股份公司 |
具有修饰的fc区域和改变的与fc受体的结合的抗原结合分子
|
|
AR053272A1
(es)
|
2005-05-11 |
2007-04-25 |
Hoffmann La Roche |
Determinacion de responsivos a la quimioterapia
|
|
US9006240B2
(en)
|
2005-08-02 |
2015-04-14 |
Eisai R&D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
|
CN101370525B
(zh)
|
2005-08-19 |
2013-09-18 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
|
EP2500359A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
CA2620195A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
|
KR100990590B1
(ko)
*
|
2005-09-01 |
2010-10-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
붕해성이 개선된 의약 조성물의 제조 방법
|
|
CA2624189A1
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
KR101353763B1
(ko)
|
2005-11-07 |
2014-01-21 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용
|
|
US20090247576A1
(en)
*
|
2005-11-22 |
2009-10-01 |
Eisai R & D Management Co., Ltd. |
Anti-tumor agent for multiple myeloma
|
|
CA2632866A1
(en)
*
|
2005-12-01 |
2007-06-07 |
Domantis Limited |
Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
|
|
US8388958B2
(en)
*
|
2006-02-06 |
2013-03-05 |
Metheresis Translational Research Sa |
Anti-MET monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
|
|
WO2007111965A2
(en)
*
|
2006-03-22 |
2007-10-04 |
Genimmune N.V. |
Hepatitis c virus neutralizing antibodies
|
|
AU2007241130A1
(en)
|
2006-03-31 |
2007-11-01 |
EMD Serono Research Centre, Inc. |
Treatment of tumors expressing mutant EGF receptors
|
|
CN101443009A
(zh)
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
|
WO2007137984A2
(en)
|
2006-05-25 |
2007-12-06 |
Glaxo Group Limited |
Modified humanised anti-interleukin-18 antibodies
|
|
JPWO2008001956A1
(ja)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝線維症治療剤
|
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
WO2008026748A1
(fr)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
|
EP2061906B1
(en)
|
2006-09-12 |
2011-08-31 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
|
|
CU23612A1
(es)
*
|
2006-09-29 |
2010-12-08 |
Centro Inmunologia Molecular |
Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
|
|
TW200833711A
(en)
*
|
2006-12-22 |
2008-08-16 |
Genentech Inc |
Antibodies to insulin-like growth factor receptor
|
|
EP2094303A1
(en)
*
|
2006-12-22 |
2009-09-02 |
Novelix Therapeutics Gmbh |
Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
|
|
CN104043123B
(zh)
*
|
2007-01-25 |
2019-08-13 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
|
CA2676049C
(en)
*
|
2007-03-01 |
2018-04-10 |
Symphogen A/S |
Recombinant anti-epidermal growth factor receptor antibody compositions
|
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
|
AU2008227123B2
(en)
*
|
2007-03-15 |
2014-03-27 |
Ludwig Institute For Cancer Research Ltd. |
Treatment method using EGFR antibodies and src inhibitors and related formulations
|
|
CA2683801A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
|
ES2583377T3
(es)
|
2007-06-08 |
2016-09-20 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
|
MX2010001757A
(es)
|
2007-08-14 |
2010-09-14 |
Ludwig Inst Cancer Res |
Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
|
|
MX2010004259A
(es)
*
|
2007-10-19 |
2010-08-31 |
Pharma Mar Sa |
Tratamientos antitumorales mejorados.
|
|
JP5638244B2
(ja)
|
2007-11-09 |
2014-12-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
|
AR069333A1
(es)
*
|
2007-11-15 |
2010-01-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos monoclonales que se unen al receptor tirosin quinasa anexelekto (axl), hibridomas que los producen y sus usos
|
|
EP4098661A1
(en)
|
2007-12-26 |
2022-12-07 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
|
WO2009096377A1
(ja)
*
|
2008-01-29 |
2009-08-06 |
Eisai R & D Management Co., Ltd. |
血管阻害物質とタキサンとの併用
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
JP2011515330A
(ja)
*
|
2008-01-30 |
2011-05-19 |
ファルマ・マール・ソシエダード・アノニマ |
改良抗腫瘍治療剤
|
|
WO2009109649A1
(en)
*
|
2008-03-07 |
2009-09-11 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
RU2010153580A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
|
US9109026B2
(en)
*
|
2008-06-03 |
2015-08-18 |
Abbvie, Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
CN101602808B
(zh)
*
|
2008-06-12 |
2012-06-20 |
上海市肿瘤研究所 |
特异性结合蛋白及其使用
|
|
BRPI0914209A2
(pt)
*
|
2008-06-20 |
2015-11-03 |
Centro Inmunologia Molecular |
inibidor do receptor do fator de crscimento epidérmico, linha celular, composição farmacêutica, usos do inibidor e de um anticorpo e método
|
|
MX2010014574A
(es)
*
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
|
US8663640B2
(en)
*
|
2008-08-29 |
2014-03-04 |
Symphogen A/S |
Methods using recombinant anti-epidermal growth factor receptor antibody compositions
|
|
CN110317272A
(zh)
|
2008-10-14 |
2019-10-11 |
霍夫曼-拉罗奇有限公司 |
免疫球蛋白变体及其用途
|
|
CN102271707B
(zh)
|
2008-10-29 |
2015-04-08 |
阿布林克斯公司 |
单域抗原结合性分子的制剂
|
|
JP6113404B2
(ja)
|
2008-10-29 |
2017-04-12 |
アブリンクス エン．ヴェー． |
単一ドメイン抗原結合分子の精製方法
|
|
US20100233079A1
(en)
*
|
2008-12-04 |
2010-09-16 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
CN102272319B
(zh)
*
|
2009-01-08 |
2014-08-27 |
伯乐实验室公司 |
用于提高核酸扩增反应效率的方法和组合物
|
|
EP2210903A1
(en)
*
|
2009-01-21 |
2010-07-28 |
Monoclonal Antibodies Therapeutics |
Anti-CD160 monoclonal antibodies and uses thereof
|
|
TWI541021B
(zh)
|
2009-03-05 |
2016-07-11 |
艾伯維有限公司 |
Ｉｌ－１７結合蛋白
|
|
MA33198B1
(fr)
|
2009-03-20 |
2012-04-02 |
Genentech Inc |
Anticorps anti-her di-spécifiques
|
|
WO2010112413A1
(en)
|
2009-03-31 |
2010-10-07 |
Roche Glycart Ag |
Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
|
|
AR075982A1
(es)
|
2009-03-31 |
2011-05-11 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
|
|
BRPI1014449A2
(pt)
|
2009-04-07 |
2017-06-27 |
Roche Glycart Ag |
anticorpos biespecíficos anti-erbb-2/ anti-c-met.
|
|
KR20120024763A
(ko)
|
2009-05-15 |
2012-03-14 |
추가이 세이야쿠 가부시키가이샤 |
항ａｘｌ 항체
|
|
US20100316639A1
(en)
|
2009-06-16 |
2010-12-16 |
Genentech, Inc. |
Biomarkers for igf-1r inhibitor therapy
|
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
ES2354922B1
(es)
|
2009-09-02 |
2012-02-07 |
Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron |
Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
CN102666875A
(zh)
|
2009-10-15 |
2012-09-12 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP2494070A2
(en)
|
2009-10-30 |
2012-09-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
|
CN101875695B
(zh)
*
|
2009-11-11 |
2012-07-04 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗体及其编码基因与应用
|
|
CN101704891B
(zh)
*
|
2009-11-11 |
2011-11-09 |
中国人民解放军军事医学科学院生物工程研究所 |
一种针对表皮生长因子受体的抗体及其编码基因与应用
|
|
EP2507381A4
(en)
|
2009-12-04 |
2016-07-20 |
Hoffmann La Roche |
PLURISPECIFIC ANTIBODIES, ANTIBODY ANALOGUES, COMPOSITIONS AND METHODS
|
|
RU2012132278A
(ru)
|
2010-01-12 |
2014-02-20 |
Ф. Хоффманн-Ля Рош Аг |
Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
|
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
|
US20110189178A1
(en)
*
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
|
MX2012008958A
(es)
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
|
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
|
CA2800230A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
|
MX2012010265A
(es)
|
2010-03-17 |
2012-10-01 |
Hoffmann La Roche |
Compuestos de imidazopiridina, composiciones y metodos de uso.
|
|
CA2794745A1
(en)
|
2010-03-29 |
2011-10-06 |
Zymeworks, Inc. |
Antibodies with enhanced or suppressed effector function
|
|
CN101875697B
(zh)
*
|
2010-04-15 |
2014-04-30 |
北京天广实生物技术股份有限公司 |
新型抗egfr人源抗体tgm10的设计及其应用
|
|
BR112012026470A2
(pt)
|
2010-04-16 |
2016-08-09 |
Genentech Inc |
método para prever a sensibilidade de crescimento de células tumorais e para tratar um tumor em um paciente
|
|
LT2571532T
(lt)
|
2010-05-14 |
2017-08-10 |
Abbvie Inc. |
Il-1 surišantys baltymai
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP3029066B1
(en)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
PE20131412A1
(es)
|
2010-08-03 |
2014-01-19 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
TW201211252A
(en)
|
2010-08-26 |
2012-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
DK2612151T3
(en)
|
2010-08-31 |
2017-10-02 |
Genentech Inc |
BIOMARKETS AND METHODS OF TREATMENT
|
|
TW201217387A
(en)
|
2010-09-15 |
2012-05-01 |
Hoffmann La Roche |
Azabenzothiazole compounds, compositions and methods of use
|
|
AU2011320314B2
(en)
|
2010-10-29 |
2015-08-06 |
Immunogen, Inc. |
Novel EGFR-binding molecules and immunoconjugates thereof
|
|
AU2011320318B9
(en)
|
2010-10-29 |
2015-11-19 |
Immunogen, Inc. |
Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
|
|
WO2012065161A2
(en)
|
2010-11-12 |
2012-05-18 |
Scott & White Healthcare |
Antibodies to tumor endothelial marker 8
|
|
CN103313987A
(zh)
|
2010-11-19 |
2013-09-18 |
弗·哈夫曼-拉罗切有限公司 |
吡唑并吡啶化合物、吡唑并吡啶化合物以及它们作为tyk2抑制剂的用途
|
|
PE20141060A1
(es)
|
2010-12-21 |
2014-09-26 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
|
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
|
CN102153648B
(zh)
*
|
2011-01-27 |
2012-07-04 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗egfr人源化抗体l4-h3及其编码基因与应用
|
|
EP2700403B1
(en)
|
2011-04-18 |
2015-11-25 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
|
CA2837169C
(en)
|
2011-05-24 |
2021-11-09 |
Zyngenia, Inc. |
Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
|
|
EP2714937B1
(en)
|
2011-06-03 |
2018-11-14 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
EP2721174A1
(en)
|
2011-06-20 |
2014-04-23 |
Traslational Cancer Drugs Pharma, S.L. |
Method for predicting the clinical response to chemotherapy in a subject with cancer
|
|
WO2019071023A1
(en)
|
2017-10-04 |
2019-04-11 |
Yale University |
COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
|
|
US9464288B2
(en)
|
2011-07-11 |
2016-10-11 |
Yale University |
Compositions and methods for making selenocysteine containing polypeptides
|
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
|
EP2742040B1
(en)
|
2011-08-12 |
2016-04-06 |
F.Hoffmann-La Roche Ag |
Indazole compounds, compositions and methods of use
|
|
CA2842375A1
(en)
|
2011-08-17 |
2013-02-21 |
Erica Jackson |
Neuregulin antibodies and uses thereof
|
|
MX2014002949A
(es)
|
2011-09-20 |
2014-04-30 |
Hoffmann La Roche |
Compuesto de imidazopiridina, composiciones y metodos de uso.
|
|
DK2766392T3
(da)
|
2011-10-10 |
2019-10-07 |
Xencor Inc |
Fremgangsmåde til oprensning af antistoffer
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
EP2766497A1
(en)
|
2011-10-13 |
2014-08-20 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
|
TW201323440A
(zh)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
抗骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）之免疫結合物
|
|
MX2014006087A
(es)
|
2011-11-21 |
2014-08-01 |
Immunogen Inc |
Metodo de tratamiento de tumores que son resistentes a terapias contra el receptor del factor de crecimiento epidermico (egfr) con agentes citotoxicos conjugados con anticuerpos dirigidos contra el receptor del factor de crecimiento epidermico.
|
|
WO2013078223A1
(en)
*
|
2011-11-23 |
2013-05-30 |
Children's Hospital & Research Center Oakland |
Anti-factor h binding protein antibodies and methods of use thereof
|
|
AU2012346540C1
(en)
|
2011-11-30 |
2019-07-04 |
Genentech, Inc. |
ErbB3 mutations in cancer
|
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
|
|
AU2013240261A1
(en)
|
2012-03-27 |
2014-09-18 |
Genentech, Inc. |
Diagnosis and treatments relating to HER3 inhibitors
|
|
AU2012380717B2
(en)
|
2012-05-24 |
2018-08-16 |
Fundacio Institucio Catalana De Recerca I Estudis Avancats |
Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
|
|
PL2859017T3
(pl)
|
2012-06-08 |
2019-07-31 |
Sutro Biopharma, Inc. |
Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
|
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
|
CN104981254B
(zh)
|
2012-08-31 |
2018-05-22 |
苏特罗生物制药公司 |
含有叠氮基的经修饰的氨基酸
|
|
LT2839860T
(lt)
|
2012-10-12 |
2019-07-10 |
Medimmune Limited |
Pirolobenzodiazepinai ir jų konjugatai
|
|
WO2014063205A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
|
TW202033215A
(zh)
|
2012-11-01 |
2020-09-16 |
美商艾伯維有限公司 |
穩定雙重可變區域免疫球蛋白蛋白質調配物
|
|
KR20190107184A
(ko)
|
2012-11-01 |
2019-09-18 |
애브비 인코포레이티드 |
항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
SI3447069T1
(sl)
|
2012-11-21 |
2021-02-26 |
Janssen Biotech, Inc. |
Bispecifična protitelesa EGFR/C-MET
|
|
BR112015009004A8
(pt)
|
2012-12-21 |
2021-07-20 |
Eisai R&D Man Co Ltd |
forma amorfa de derivado de quinolina e método de produção da mesma
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA3211863A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
AU2014207549B2
(en)
|
2013-01-15 |
2018-12-06 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CA2900097A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
|
EP2964260A2
(en)
|
2013-03-06 |
2016-01-13 |
F. Hoffmann-La Roche AG |
Methods of treating and preventing cancer drug resistance
|
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
|
RU2015143517A
(ru)
|
2013-03-13 |
2017-04-19 |
Дженентек, Инк. |
Пиразолсодержащие соединения и их применения
|
|
CN105307683A
(zh)
|
2013-03-14 |
2016-02-03 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|
|
BR112015022576A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
|
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
|
US10544187B2
(en)
|
2013-03-15 |
2020-01-28 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US20140377253A1
(en)
|
2013-03-15 |
2014-12-25 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
BR112015023203A8
(pt)
|
2013-03-15 |
2018-01-23 |
Constellation Pharmaceuticals Inc |
métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
|
ES2687968T3
(es)
|
2013-05-14 |
2018-10-30 |
Eisai R&D Management Co., Ltd. |
Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
|
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
|
CA2922925A1
(en)
|
2013-09-05 |
2015-03-12 |
Genentech, Inc. |
Antiproliferative compounds
|
|
AU2014318545A1
(en)
|
2013-09-12 |
2016-03-24 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
|
WO2015049325A1
(en)
|
2013-10-03 |
2015-04-09 |
F. Hoffmann-La Roche Ag |
Therapeutic inhibitors of cdk8 and uses thereof
|
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
|
CA2925598A1
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
|
WO2015073721A1
(en)
|
2013-11-13 |
2015-05-21 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
|
|
AU2014364601A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
|
|
US20150190506A1
(en)
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
PE20160996A1
(es)
|
2013-12-23 |
2016-11-09 |
Bayer Pharma AG |
Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp
|
|
JP2017516458A
(ja)
|
2014-03-24 |
2017-06-22 |
ジェネンテック， インコーポレイテッド |
ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
|
|
AU2015237184B2
(en)
|
2014-03-28 |
2020-11-26 |
Xencor, Inc. |
Bispecific antibodies that bind to CD38 and CD3
|
|
KR20160145624A
(ko)
|
2014-03-31 |
2016-12-20 |
제넨테크, 인크. |
항-ox40 항체 및 사용 방법
|
|
EP3126386A1
(en)
|
2014-03-31 |
2017-02-08 |
F. Hoffmann-La Roche AG |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
US20170158749A1
(en)
*
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
CN104152415B
(zh)
*
|
2014-08-13 |
2015-09-30 |
百泰生物药业有限公司 |
获得高产稳定表达重组抗体的骨髓瘤细胞株的方法及应用
|
|
HRP20221047T1
(hr)
|
2014-08-28 |
2022-11-11 |
Eisai R&D Management Co., Ltd. |
Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
|
|
EP3189046B1
(en)
|
2014-09-05 |
2020-08-26 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CN106687141A
(zh)
|
2014-09-10 |
2017-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其缀合物
|
|
EP3193866A1
(en)
|
2014-09-19 |
2017-07-26 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
|
WO2016057924A1
(en)
|
2014-10-10 |
2016-04-14 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
|
JP6889660B2
(ja)
|
2014-10-23 |
2021-06-18 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
抗ｎｋｇ２ａ剤を用いた癌の処置
|
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
CA2966523A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
SG11201703376QA
(en)
|
2014-11-06 |
2017-05-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
JP6639497B2
(ja)
|
2014-11-10 |
2020-02-05 |
ジェネンテック， インコーポレイテッド |
ブロモドメインインヒビターおよびその使用
|
|
CN106999583A
(zh)
|
2014-11-17 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
|
TN2017000222A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CU24597B1
(es)
|
2014-11-26 |
2022-05-11 |
Xencor Inc |
Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
|
|
US9763922B2
(en)
|
2014-11-27 |
2017-09-19 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
US10398774B2
(en)
|
2014-12-09 |
2019-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies against AXL
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
CN107109491A
(zh)
|
2014-12-23 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
用于治疗和诊断化学疗法抗性癌症的组合物和方法
|
|
CN107208138A
(zh)
|
2014-12-30 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
用于癌症预后和治疗的方法和组合物
|
|
CN107406418B
(zh)
|
2015-01-09 |
2021-10-29 |
基因泰克公司 |
4,5-二氢咪唑衍生物及其作为组蛋白脱甲基酶(kdm2b)抑制剂的用途
|
|
CN107406414B
(zh)
|
2015-01-09 |
2022-04-19 |
基因泰克公司 |
作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物
|
|
CN107406429B
(zh)
|
2015-01-09 |
2021-07-06 |
基因泰克公司 |
哒嗪酮衍生物及其在治疗癌症中的用途
|
|
CN107531692B
(zh)
|
2015-01-29 |
2020-12-25 |
基因泰克公司 |
治疗化合物及其用途
|
|
WO2016123387A1
(en)
|
2015-01-30 |
2016-08-04 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
PT3263106T
(pt)
|
2015-02-25 |
2024-01-12 |
Eisai R&D Man Co Ltd |
Método para suprimir o amargor do derivado de quinolina
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
CN107709364A
(zh)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
具有激动剂活性的抗原结合复合体及使用方法
|
|
IL295002A
(en)
|
2015-05-12 |
2022-09-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
|
|
KR20180012753A
(ko)
|
2015-05-29 |
2018-02-06 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
KR20180025888A
(ko)
|
2015-06-08 |
2018-03-09 |
제넨테크, 인크. |
항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
|
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
RU2729936C2
(ru)
|
2015-06-16 |
2020-08-13 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противораковое средство
|
|
KR20180018538A
(ko)
|
2015-06-17 |
2018-02-21 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
|
SG11201710639YA
(en)
|
2015-06-22 |
2018-01-30 |
Bayer Pharma AG |
Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
|
|
KR20180020225A
(ko)
|
2015-06-23 |
2018-02-27 |
바이엘 파마 악티엔게젤샤프트 |
Ksp 억제제의 표적화된 접합체
|
|
EP3328426B8
(en)
*
|
2015-07-27 |
2021-06-02 |
InnoCIMAb Pte Ltd |
Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr)
|
|
CN108026110B
(zh)
|
2015-08-26 |
2022-02-08 |
国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.Cnio) |
作为蛋白激酶抑制剂的稠合三环化合物
|
|
IL307276A
(en)
|
2015-08-28 |
2023-11-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
WO2017041027A1
(en)
|
2015-09-04 |
2017-03-09 |
Obi Pharma, Inc. |
Glycan arrays and method of use
|
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
|
CN105237638A
(zh)
*
|
2015-10-26 |
2016-01-13 |
无锡傲锐东源生物科技有限公司 |
抗egfr蛋白单克隆抗体杂交瘤细胞及其产生的抗egfr单克隆抗体和应用
|
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
DK3389662T3
(da)
|
2015-12-16 |
2022-02-28 |
Genentech Inc |
Fremgangsmåde til fremstilling af tricykliske PI3K-inhibitorforbindelser og fremgangsmåder til anvendelse af disse til behandling af cancer
|
|
EP3862365A1
(en)
|
2016-01-08 |
2021-08-11 |
F. Hoffmann-La Roche AG |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
KR20180127320A
(ko)
|
2016-03-14 |
2018-11-28 |
유니버시티에트 이 오슬로 |
변경된 FcRn 결합을 갖는 조작된 면역글로불린
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
CN109311995A
(zh)
|
2016-03-29 |
2019-02-05 |
台湾浩鼎生技股份有限公司 |
抗体、药物组合物和方法
|
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
MX2018012492A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para monitorear y tratar el cáncer.
|
|
AU2017248766A1
(en)
|
2016-04-15 |
2018-11-01 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
KR20180128496A
(ko)
|
2016-04-22 |
2018-12-03 |
오비아이 파머 인코퍼레이티드 |
글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
|
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
|
EP4067347A1
(en)
|
2016-05-24 |
2022-10-05 |
Genentech, Inc. |
Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer
|
|
CN109476663B
(zh)
|
2016-05-24 |
2021-11-09 |
基因泰克公司 |
用于治疗癌症的吡唑并吡啶衍生物
|
|
WO2017214373A1
(en)
|
2016-06-08 |
2017-12-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2017218707A2
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
EP3471776B1
(en)
|
2016-06-15 |
2022-05-04 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
|
|
EP3472197A1
(en)
|
2016-06-15 |
2019-04-24 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
CN108472371B
(zh)
*
|
2016-07-05 |
2022-05-24 |
江苏恒瑞医药股份有限公司 |
Egfr抗体-药物偶联物及其在医药上的应用
|
|
CN110072545A
(zh)
|
2016-07-27 |
2019-07-30 |
台湾浩鼎生技股份有限公司 |
免疫原性/治疗性聚糖组合物及其用途
|
|
JP7121724B2
(ja)
|
2016-07-29 |
2022-08-18 |
オービーアイ ファーマ，インコーポレイテッド |
ヒト抗体、医薬組成物及び方法
|
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック， インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
|
JP7142630B2
(ja)
|
2016-10-14 |
2022-09-27 |
ゼンコア インコーポレイテッド |
ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質
|
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
|
CA3044274A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
|
WO2018114578A1
(de)
|
2016-12-21 |
2018-06-28 |
Bayer Pharma Aktiengesellschaft |
Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
|
|
CN110072556B
(zh)
|
2016-12-21 |
2023-05-02 |
拜耳制药股份公司 |
具有ksp抑制剂的特异性抗体药物缀合物(adc)
|
|
CA3052670A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
MX2019012187A
(es)
|
2017-04-13 |
2019-11-25 |
Hoffmann La Roche |
Un inmunoconjugado de interleuquina-2, un agonista de cd40 y opcionalmente un antagonista de union al eje pd-1 para uso en metodos para tratar cancer.
|
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
|
TWI823859B
(zh)
|
2017-07-21 |
2023-12-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
CA3070297A1
(en)
|
2017-08-11 |
2019-02-14 |
Genentech, Inc. |
Anti-cd8 antibodies and uses thereof
|
|
JP2020532982A
(ja)
|
2017-09-08 |
2020-11-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの診断及び治療方法
|
|
AU2018359967A1
(en)
|
2017-11-06 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
CU24558B1
(es)
|
2017-11-28 |
2021-12-08 |
Ct Inmunologia Molecular |
Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados
|
|
WO2019125732A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
TW202000702A
(zh)
|
2018-02-26 |
2020-01-01 |
美商建南德克公司 |
用於抗ｔｉｇｉｔ拮抗劑抗體及抗ｐｄ－ｌ１拮抗劑抗體治療之投藥
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
JP2021521784A
(ja)
|
2018-04-18 |
2021-08-30 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
|
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
US20210363590A1
(en)
|
2018-05-21 |
2021-11-25 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
|
WO2019224275A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US20200030443A1
(en)
|
2018-06-23 |
2020-01-30 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
TW202035444A
(zh)
|
2018-06-27 |
2020-10-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
|
KR20210034622A
(ko)
|
2018-07-18 |
2021-03-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
|
|
WO2020028909A1
(en)
|
2018-08-03 |
2020-02-06 |
Brown University |
Oral formulations with increased uptake
|
|
TW202024023A
(zh)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
|
JP2022501332A
(ja)
|
2018-09-19 |
2022-01-06 |
ジェネンテック， インコーポレイテッド |
膀胱がんの治療方法および診断方法
|
|
ES2955032T3
(es)
|
2018-09-21 |
2023-11-28 |
Hoffmann La Roche |
Métodos de diagnóstico para el cáncer de mama triple negativo
|
|
CN113195523A
(zh)
|
2018-10-03 |
2021-07-30 |
Xencor股份有限公司 |
IL-12异源二聚体Fc融合蛋白
|
|
CN113329769A
(zh)
|
2018-10-11 |
2021-08-31 |
斯克里普斯研究学院 |
具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
|
|
WO2020081767A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
CN113056288A
(zh)
|
2018-11-20 |
2021-06-29 |
康奈尔大学 |
放射性核素的大环配合物及其在癌症的放射治疗中的应用
|
|
CN113474337A
(zh)
|
2018-12-19 |
2021-10-01 |
奥瑞生物药品公司 |
作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
|
|
EP3898626A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
CN113330033A
(zh)
|
2018-12-26 |
2021-08-31 |
先天制药公司 |
白细胞免疫球蛋白样受体2中和性抗体
|
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
MX2021010313A
(es)
|
2019-02-27 |
2021-09-23 |
Genentech Inc |
Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
|
|
WO2020172712A1
(en)
|
2019-02-27 |
2020-09-03 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
WO2020226986A2
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
|
EP3980423A1
(en)
|
2019-06-10 |
2022-04-13 |
Sutro Biopharma, Inc. |
5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
|
|
EP3983410A1
(en)
|
2019-06-17 |
2022-04-20 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
CR20220095A
(es)
|
2019-09-04 |
2022-06-06 |
Genentech Inc |
Agentes de unión a cd8 y usos de los mismos
|
|
JP2022548978A
(ja)
|
2019-09-27 |
2022-11-22 |
ジェネンテック， インコーポレイテッド |
薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
|
|
US20230024096A1
(en)
|
2019-10-29 |
2023-01-26 |
Hoffmann-La Roche Inc. |
Bifunctional compounds for the treatment of cancer
|
|
IL292458A
(en)
|
2019-11-06 |
2022-06-01 |
Genentech Inc |
Diagnostic and treatment methods for the treatment of hematological cancer
|
|
CN114728905A
(zh)
|
2019-11-13 |
2022-07-08 |
基因泰克公司 |
治疗性化合物及使用方法
|
|
AU2020403145A1
(en)
|
2019-12-13 |
2022-07-07 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
|
AU2020408562A1
(en)
|
2019-12-20 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
EP3915576A1
(en)
|
2020-05-28 |
2021-12-01 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Chimeric antigen receptors specific for p95her2 and uses thereof
|
|
KR20230025691A
(ko)
|
2020-06-16 |
2023-02-22 |
제넨테크, 인크. |
삼중 음성 유방암을 치료하기 위한 방법과 조성물
|
|
KR20230024368A
(ko)
|
2020-06-18 |
2023-02-20 |
제넨테크, 인크. |
항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
|
|
CN115843335A
(zh)
|
2020-06-30 |
2023-03-24 |
国家医疗保健研究所 |
用于预测患有实体癌的患者在术前辅助治疗和根治性手术后复发和/或死亡风险的方法
|
|
CN115997123A
(zh)
|
2020-06-30 |
2023-04-21 |
国家医疗保健研究所 |
用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
|
|
EP3939999A1
(en)
|
2020-07-14 |
2022-01-19 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック， インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
CN116601176A
(zh)
|
2020-09-30 |
2023-08-15 |
中国科学院动物研究所 |
靶向egfr的嵌合抗原受体
|
|
CN116406291A
(zh)
|
2020-10-05 |
2023-07-07 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
WO2022103983A2
(en)
|
2020-11-11 |
2022-05-19 |
Sutro Biopharma, Inc. |
Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
PE20231505A1
(es)
|
2021-02-12 |
2023-09-26 |
Hoffmann La Roche |
Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
WO2022192403A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
AU2022280025A1
(en)
|
2021-05-25 |
2023-12-07 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
|
EP4356926A1
(en)
|
2021-06-14 |
2024-04-24 |
Centro de Inmunologia Molecular |
Use of monoclonal antibodies against the epidermal growth factor receptor in the treatment of patients with acute hypoxaemic respiratory failure
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
|
TW202321261A
(zh)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
選擇性ｋｒａｓ抑制劑
|
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
|
CU20210104A7
(es)
|
2021-12-21 |
2023-07-12 |
Ct Inmunologia Molecular |
Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2
|
|
WO2023164487A1
(en)
|
2022-02-22 |
2023-08-31 |
Brown University |
Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
|
|
EP4253418A1
(en)
|
2022-03-29 |
2023-10-04 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
|
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
|
US20240091365A1
(en)
|
2022-06-27 |
2024-03-21 |
Sutro Biopharma, Inc. |
Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
|
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024015229A1
(en)
|
2022-07-15 |
2024-01-18 |
Sutro Biopharma, Inc. |
Protease/enzyme cleavable linker-payloads and protein conjugates
|
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|